Global Antibody Drug Conjugates Contract Manufacturing Market Size & Outlook
Global antibody drug conjugates contract manufacturing market, 2018-2030 (US$M)
Related Markets
Global antibody drug conjugates contract manufacturing market highlights
- The global antibody drug conjugates contract manufacturing market generated a revenue of USD 9,754.0 million in 2022 and is expected to reach USD 25,798.9 million by 2030.
- The market is expected to grow at a CAGR (2023 - 2030) of 12.9% by 2030.
- In terms of segment, myeloma accounted for a revenue of USD 4,829.6 million in 2022.
- Lymphoma is the most lucrative condition segment registering the fastest growth during the forecast period.
- In terms of region, Asia Pacific was the largest revenue generating market in 2022.
- Country-wise, Japan is expected to register the highest CAGR from 2023 to 2030.
Global data book summary
| Market revenue in 2022 | USD 9,754.0 million |
| Market revenue in 2030 | USD 25,798.9 million |
| Growth rate | 12.9% (CAGR from 2022 to 2030) |
| Largest segment | Myeloma |
| Fastest growing segment | Lymphoma |
| Historical data covered | 2018 - 2021 |
| Base year for estimation | 2022 |
| Forecast period covered | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Myeloma, Lymphoma, Breast Cancer |
Other key industry trends
- In terms of revenue, the North America accounted for 24.4% of the global antibody drug conjugates contract manufacturing market in 2022.
- By country, the U.S. is projected to lead the global market in terms of revenue in 2030.
- By country, Japan is the fastest growing regional market and is projected to reach USD 1,313.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Contract Manufacturing Market Scope
Antibody Drug Conjugates Contract Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Global antibody drug conjugates contract manufacturing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to antibody drug conjugates contract manufacturing market will help companies and investors design strategic landscapes.
Myeloma was the largest segment with a revenue share of 49.51% in 2022. Horizon Databook has segmented the Global antibody drug conjugates contract manufacturing market based on myeloma, lymphoma, breast cancer covering the revenue growth of each sub-segment from 2018 to 2030.
- Global Antibody Drug Conjugates Contract Manufacturing Condition Outlook (Revenue, USD Million, 2018-2030)
- Myeloma
- Lymphoma
- Breast Cancer
- Others
- Global Antibody Drug Conjugates Contract Manufacturing Linker Outlook (Revenue, USD Million, 2018-2030)
- Cleavable Linker
- Non-cleavable Linker
Reasons to subscribe to Global antibody drug conjugates contract manufacturing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Global antibody drug conjugates contract manufacturing market databook
-
Our clientele includes a mix of antibody drug conjugates contract manufacturing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of global-level data and insights on the Global antibody drug conjugates contract manufacturing market , including forecasts for subscribers. This global databook contains high-level insights into Global antibody drug conjugates contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Global antibody drug conjugates contract manufacturing market size, by regions, 2018-2030 (US$M)
Top 10 countries: Antibody drug conjugates contract manufacturing market size, 2022 (US$M)
Global antibody drug conjugates contract manufacturing market share, by condition, 2022 & 2030 (%, US$M)
Antibody drug conjugates contract manufacturing market: Opportunity assessment by country
Global antibody drug conjugates contract manufacturing market, by region, 2022 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
